FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant production of viral antigen proteins, and can be used to produce hemagglutinin protein HA/H5 of influenza A (H5N8) virus. Disclosed is an H5 gene coding a stabilized form of the HA/H5 protein of the influenza A (H5N8) virus, a recombinant plasmid DNA pVAX-H5 containing said H5 gene, and HA/H5 hemagglutinin protein produced by recombinant plasmid DNA pVAX-H5 in eukaryotic cells (animal body) and inducing a specific immune response against highly pathogenic influenza A (H5N8) virus.
EFFECT: invention makes it possible to create a DNA vaccine capable of inducing HA/H5-specific humoral and cellular response for protection against disease caused by influenza A (H5N8) virus.
3 cl, 10 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PLASMID DNA pVL3-HA/H5 CARRYING INFLUENZA A (H5N8) VIRUS HEMAGGLUTININ GENE, A RECOMBINANT STRAIN OF CHINESE HAMSTER OVARY CELL LINE CHO-K1-H5 AND RECOMBINANT HEMAGGLUTININ OF INFLUENZA A (H5N8) VIRUS, PRODUCED BY CHO-K1-H5 STRAIN AND INTENDED FOR CREATION OF PREVENTIVE PREPARATIONS AND SEROLOGICAL DIAGNOSIS OF INFLUENZA A H5N8 VIRUS | 2024 |
|
RU2827202C1 |
| RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING H5 HEMAGGLUTININ OF AVIAN INFLUENZA VIRUS | 2007 |
|
RU2441070C2 |
| RECOMBINANT PSEUDO-ADENOVIRUS PARTICLE BASED ON GENOME OF HUMAN ADENOVIRUS OF SEROTYPE 5, PRODUCING INFLUENZA HEMAGGLUTININ OF STRAIN A/Brisbane/59/2007(H1N1) AND METHOD OF ITS USE | 2012 |
|
RU2523599C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| CONJUGATE OF THE RECEPTOR-BINDING DOMAIN (RBD) PROTEIN OF SARS-CoV-2 SURFACE GLYCOPROTEIN S WITH POLYGLUCIN-SPERMIDINE (PGS) POLYMER AND VACCINE COMPLEX AGAINST CORONAVIRUS INFECTION COVID-19 BASED ON THE SPECIFIED CONJUGATE AND PLASMID DNA PVAX-RBD | 2022 |
|
RU2781294C1 |
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
| RECOMBINANT INFLUENZA VIRUS A | 2001 |
|
RU2280690C2 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
